CD274 and neoplasm: For D2A1-M1 and -M2 lines, tumor-bearing mice were treated for two weeks with GDC-0339 alone (100 mg/kg, daily, six days/week: the maximum tolerated dose is approximately 300 mg/kg31), anti-PD-1 or -PD-L1 antibody alone (12 mg/kg, twice a week/3 days apart), or GDC-0339 and anti-PD-1 or -PD-L1 antibody combined (Fig. 4a).